Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Varoglutamstat provides a unique dual mechanism of action addressing multiple pathogenic contributors to the disease cascade. VIVA-MIND provides a novel and efficient trial design to establish its optimal dosing, safety, tolerability, and efficacy in early AD.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2024-10-18
DOI
https://doi.org/10.3233/jad-231126
Citations
12
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
3.92

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Amanda Smith, Carolyn Revta, Yuqi Qiu, January Durant et al.
12 citations
Journal of Alzheimer s Disease
Alzheimer's disease research and treatments
3.92
article

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Amanda Smith, Carolyn Revta, Yuqi Qiu, January Durant, Howard Feldman, Diane M. Jacobs, Jody‐Lynn Lupo, Marwan Sabbagh, Karen Messer, David P. Salmon, Mari L. DeMarco, Raymond Scott Turner, Lorna M. Lopez, Frank Weber, Gabriel C. Léger, Archana Balasubramanian, Douglas Galasko, Kerstin Kuehn-Wache, Tanja Wassmann, Sylvia Schell-Mader
article en
12 citations

Abstract

Varoglutamstat provides a unique dual mechanism of action addressing multiple pathogenic contributors to the disease cascade. VIVA-MIND provides a novel and efficient trial design to establish its optimal dosing, safety, tolerability, and efficacy in early AD.

Journal of Alzheimer s DiseaseVol. 101(s1)
Providence Health Care (CA), Barrow Neurological Institute (US), University of British Columbia (CA), University of Pittsburgh (US), Georgetown University (US), University of California San Diego (US), Alzheimer’s Disease Neuroimaging Initiative (US), USF Health Byrd Alzheimer's Institute (US), Ribon Therapeutics (United States) (US), East China Normal University (CN)
Florida Department of Health, Ohio State University, Emory University, Northwestern University, Syracuse University, State University of New York, Georgetown University, University of South Florida, Cedars-Sinai Medical Center, York University, National Institutes of Health, University of California, San Diego, University of California, Irvine, State University of New York Upstate Medical University, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Goizueta Business School, Emory University
Good health and well-being
Openalex Percentile: Top 6%
Alzheimer's disease research and treatments
3.92
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.